Skip to main content

Drug Safety Update

From:
Medicines and Healthcare products Regulatory Agency
Skip to results

109 updates

Skip to results
109 updates
About Psychiatry
  • Chloral hydrate (Welldorm) and Triclofos

    These medicines are not first-line options for insomnia.

    • Therapeutic area: Paediatrics and neonatology and 1 others
    • Published:
  • Methylphenidate: safe and effective use to treat ADHD

    Updated guidance to use methylphenidateto safely and effectively for attention deficit hyperactivity disorder (ADHD) in children of 6 years or older and adolescents.

    • Therapeutic area: Paediatrics and neonatology and 1 others
    • Published:
  • Atomoxetine: risk of psychotic or manic symptoms in children and adolescents

    Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents - consider stopping this if symptoms occur.

    • Therapeutic area: Paediatrics and neonatology and 1 others
    • Published:
  • Antidepressants: suicidal thoughts and behaviour

    Summary report on the risk of suicidal thoughts and behaviour related to antidepressants.

    • Therapeutic area: Psychiatry
    • Published:
  • Ecoflac infusion solutions: risk of air embolism

    To avoid the risk of air embolism, these products should not be infused under pressure.

    • Therapeutic area: Anaesthesia and intensive care and 22 others
    • Published:
  • Botulinum toxin products: rare but serious risks

    Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin.

    • Therapeutic area: Neurology and 1 others
    • Published:
  • Lorazepam: reduction of recommended maximum daily dose

    Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe, disabling insomnia

    • Therapeutic area: Psychiatry
    • Published:
  • Pabrinex: allergic reactions

    Rare occurrence of serious allergic reactions should not preclude use of parenteral thiamine in patients who need treatment by this route of administration.

    • Therapeutic area: Nutrition and dietetics and 1 others
    • Published:
  • Duloxetine: marketed as Cymbalta▼ and Yentreve▼ for different disorders

    Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.

    • Therapeutic area: Endocrinology, diabetology and metabolism and 2 others
    • Published: